


- 136 -


5 What is claimed:

A compound of the formulae:




wherein:

- 10 R_1 and R_1' are independently selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, $-S-C_1-C_{10}$ alkyl, C_1-C_{10} alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl, benzyl, $-O$ -benzyl, $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$;
- 15 or a moiety of the formulae:



- 137 -



R_6 is selected from H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, $-\text{C}(\text{O})\text{CH}_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{CN}$, $-\text{CF}_3$, or $-\text{OH}$;

R_7 is selected from $-(\text{CH}_2)_n\text{-COOH}$, $-(\text{CH}_2)_n\text{-N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $-(\text{CH}_2)_n\text{-NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{CF}_3$, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_3$ cycloalkyl, $\text{C}_1\text{-C}_6$ alkoxy, $-\text{NH}(\text{C}_1\text{-C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(\text{CH}_2)_n$ phenyl, phenyl, -O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, $-(\text{CH}_2)_n$ -phenyl-O-phenyl, $-(\text{CH}_2)_n$ -phenyl- CH_2 -phenyl, $-(\text{CH}_2)_n$ -O-phenyl- CH_2 -phenyl, $-(\text{CH}_2)_n$ -phenyl-(O- CH_2 -phenyl), the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_6$ alkoxy, $-\text{NH}_2$, $-\text{NO}_2$, $-\text{CF}_3$, CO_2H , or $-\text{OH}$;

R_2 is selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{C}_1\text{-C}_{10}$ alkyl, preferably $-\text{C}_1\text{-C}_6$ alkyl, $\text{C}_1\text{-C}_{10}$ alkoxy, preferably $\text{C}_1\text{-C}_6$ alkoxy, $-\text{CHO}$, $-\text{CN}$, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{NH}\text{-C}_1\text{-C}_6$ alkyl, $-\text{N}(\text{C}_1\text{-C}_6 \text{ alkyl})_2$, $-\text{N}\text{-SO}_2\text{-C}_1\text{-C}_6$ alkyl, or $-\text{SO}_2\text{-C}_1\text{-C}_6$ alkyl;

R_3 is selected from H, $-\text{CF}_3$, $\text{C}_1\text{-C}_6$ lower alkyl, $\text{C}_1\text{-C}_6$ lower alkoxy, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $-\text{C}_1\text{-C}_6$ alkyl, $-\text{C}_3\text{-C}_{10}$ cycloalkyl, $-\text{CHO}$, halogen, $(\text{CH}_2)_n\text{C}(\text{O})\text{NH}_2$ or a moiety of the formula $-\text{L}^1\text{-M}^1$:

0066260-1207960

- 138 -

5 L¹ indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-S-$, $-O-$,
 $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$,
 $C(O)C(O)X$, $-(CH_2)_n-N-(CH_2)_n-$;

10 M¹ is selected from:

a) H, the group of C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, C₃-C₁₀ cycloalkyl,
phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted
by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl,
C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$; or

15 b) a five-membered heterocyclic ring containing one or two ring
heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole,
thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline,
imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole,
20 the five-membered heterocyclic ring being optionally substituted by from 1 to 3
substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy,
preferably C₁-C₆ alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$; or

25 c) a six-membered heterocyclic ring containing one, two or three ring
heteroatoms selected from N, S or O including, but not limited to, pyran, pyridine,
pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine,
thiadiazine, oxazine, or morpholine, the six-membered heterocyclic ring being
optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl,
preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, $-CHO$, $-NO_2$, $-NH_2$,
30 $-CN$, $-CF_3$ or $-OH$; or

00677021.092900


Sub
AI

- 139 -

5 d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, chromene, indole, isoindole, indoline, isoindoline, naphthalene, purine, indolizine, indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or naphthyridine, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH;

15 R₁ is selected from the group of C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, -(CH₂)_n-C₃-C₆ cycloalkyl, -(CH₂)_n-S-(CH₂)_n-C₃-C₆ cycloalkyl, -(CH₂)_n-O-(CH₂)_n-C₃-C₆ cycloalkyl, or the groups of:

a) -(CH₂)_n-phenyl-O-phenyl, -(CH₂)_n-phenyl-CH₂-phenyl, -(CH₂)_n-O-phenyl-CH₂-phenyl, -(CH₂)_n-phenyl-(O-CH₂-phenyl)₂, or a moiety of the formulae:



wherein n is independently selected in each appearance as an integer from 0 to 3, preferably 0 to 2, more preferably 0 to 1, Y is C₃-C₅ cycloalkyl, phenyl, benzyl, naphthyl, pyridinyl, quinolyl, furyl, thienyl or pyrrolyl; rings of these groups being optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF₃, -

006260-1207960

- 140 -

- 5 OH, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$ or a five membered heterocyclic ring containing one heteroatom selected from N, S, or O, preferably S or O; or

b) a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$,
wherein A is the moiety:




wherein

D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;


B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably

- 15 1 to 2, substituents selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$; or

c) a moiety of the formulae:



- 141 -



wherein Z is O or S and the phenyl and pyrimidinyl rings of each moiety are optionally and independently substituted by from 1 to 3 substituents selected from halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, -NH₂, or -NO₂; or

d) a moiety of the formula -L²-M², wherein:

L² indicates a linking or bridging group of the formulae -(CH₂)_n-, -S-, -O-, -SO₂-, -C(O)-, -(CH₂)_n-C(O)-, -(CH₂)_n-C(O)-(CH₂)_n-, -(CH₂)_n-O-(CH₂)_n-, or -(CH₂)_n-S-(CH₂)_n-,

where X = O, N

M² is selected from the group of C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, C₃-C₁₀ cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being

- 142 -

5 optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -NO₂, -NH₂, -CN, or -CF₃; or

10 i) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -NO₂, -NH₂, -CN, or -CF₃; or

15 ii) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to pyridine, pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH; or

20

25 iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, indole, indoline, naphthalene, purine, or quinoline, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH;




30 n is an integer from 0 to 3;

09677021.092900

Sub
A1

- 143 -

- 5 R_3 is selected from $-\text{COOH}$, $-\text{C}(\text{O})-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $(\text{CH}_2)_n-\text{CH}=\text{CH}-\text{COOH}$, $-(\text{CH}_2)_n$ -tetrazole, $-\text{CH}_2$ -phenyl- $\text{C}(\text{O})$ -benzothiazole, or



or a moiety selected from the formulae $-\text{L}^3-\text{M}^3$;

- wherein L^3 is a bridging or linking moiety selected from a chemical bond, $-(\text{CH}_2)_n$, -
 15 $\text{S}-$, $-\text{O}-$, $-\text{SO}_2-$, $-\text{C}(\text{O})-$, $-(\text{CH}_2)_n-\text{C}(\text{O})-$, $-(\text{CH}_2)_n-\text{C}(\text{O})-(\text{CH}_2)_n-$, $-(\text{CH}_2)_n-\text{O}-(\text{CH}_2)_n-$,
 $(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-$, $-\text{C}(\text{Z})-\text{N}(\text{R}_6)-$, $-\text{C}(\text{Z})-\text{N}(\text{R}_6)-(\text{CH}_2)_n-$, $-\text{C}(\text{O})-\text{C}(\text{Z})-\text{N}(\text{R}_6)-$, $-\text{C}(\text{O})-$
 $\text{C}(\text{Z})-\text{N}(\text{R}_6)-(\text{CH}_2)_n-$, $-\text{C}(\text{Z})-\text{NH}-\text{SO}_2-$, $-\text{C}(\text{Z})-\text{NH}-\text{SO}_2-(\text{CH}_2)_n-$, $-(\text{CH}_2)_n-\text{S}-(\text{CH}_2)_n-$,
 $(\text{CH}_2)_n-\text{SO}-(\text{CH}_2)_n-$, $-(\text{CH}_2)_n-\text{SO}_2-(\text{CH}_2)_n-$, or $-(\text{CH}_2)_n-\text{CH}=\text{CH}-(\text{CH}_2)_n-\text{O}-$;



- M^3 is selected from the group of $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-$
 20 COOH , tetrazole,

09677021.092900

Sw
AI

- 144 -

5



10


or

where R_8 , R_9 or R_{10} can be attached anywhere in the cyclic or bicyclic system,
 n is an integer from 0 to 3;

R_8 , in each appearance, is independently selected from H, $-\text{COOH}$, $-(\text{CH}_2)_n-$
 15 COOH , $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, tetrazole, $-\text{C}(\text{O})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$,

Sub
 AI
 09677021.092900

- 145 -






n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$,
 10 $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-\text{C}_1-\text{C}_6$ alkyl, $-\text{O}-\text{C}_1-\text{C}_6$ alkyl, $-\text{NH}(\text{C}_1-\text{C}_6$ alkyl), or $-\text{N}(\text{C}_1-\text{C}_6$ alkyl);

n is an integer from 0 to 3;


R_{10} is selected from the group of H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-(\text{CH}_2)_n-\text{COOH}$,
 $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-\text{C}_1-\text{C}_6$ alkyl, $-\text{O}-\text{C}_1-\text{C}_6$ alkyl, $-\text{NH}(\text{C}_1-\text{C}_6$ alkyl), $-\text{N}(\text{C}_1-\text{C}_6$ alkyl);



006260-1202960

Sub
 Al


- 146 -




R_{11} is selected from H, C_1-C_6 lower alkyl, C_1-C_6 cycloalkyl, $-CF_3$, $-COOH$, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$,

09677021.092900
 Sub
 P1

- 147 -




with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_3 , R_8 , R_9 , R_{10} , and/or R_{11} shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,



n is an integer from 0 to 3;
 or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 of the formula:



wherein:

006260-1207960

- 148 -

5 R_1 and R_2 are independently selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, $-S-C_1-C_{10}$ alkyl, C_1-C_{10} alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl, benzyl, $-O$ -benzyl, or $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$;

10 R_2 is selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-CHO$, $-CN$, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6 \text{ alkyl})_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

15 R_3 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, $-C_1-C_6$ alkyl, $-C_3-C_{10}$ cycloalkyl, $-CHO$, halogen, or $(CH_2)_n C(O)NH_2$ or a moiety of the formula $-L^1-M^1$:

20 L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-S-$, $-O-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $C(O)C(O)X$, $-(CH_2)_n-N-(CH_2)_n-$,

25 M^1 is selected from: H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$;

R_4 is a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:

Sub
AI
cont

09677021.092900

- 149 -



wherein

D is H, C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, or -CF₃;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂; or a pharmaceutically acceptable salt thereof.


3. A compound of Claim 2 wherein R₄ is the moiety:



B and C are phenyl optionally substituted by from 1 to 3 substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂; and R₁, R₁, R₂, R₃, R₃, L¹, M¹ and D are as defined in Claim 2; or a pharmaceutically acceptable salt thereof.


4. A compound of Claim 1 having the formulae:

- 150 -



wherein:


R_1 and R_1' are independently selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, $-S-C_1-C_{10}$ alkyl, preferably $-S-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl, benzyl, $-O$ -benzyl, $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$; or R_1 and R_1' are independently a moiety of the formulae:



Sub
 A1
 cont

0967021-092900

- 151 -



Sub A1 Comp

R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)CH_3$, phenyl, $-O$ -phenyl, benzyl, $-O$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$;

15

R_7 is selected from $-(CH_2)_n-COOH$, $-(CH_2)_n-N(C_1-C_6 \text{ alkyl})_2$, $-(CH_2)_n-NH(C_1-C_6 \text{ alkyl})$, $-CF_3$, C_1-C_6 alkyl, C_3-C_6 cycloalkyl, C_1-C_6 alkoxy, $-NH(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$ phenyl, phenyl, $-O$ -phenyl, benzyl, $-O$ -benzyl, adamantyl, or morpholinyl, $-(CH_2)_n$ -phenyl- $-O$ -phenyl, $-(CH_2)_n$ -phenyl- CH_2 -phenyl, $-(CH_2)_n$ - O -phenyl- CH_2 -phenyl, $-(CH_2)_n$ -phenyl- $(-O-CH_2-phenyl)_2$, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$, $-CF_3$, CO_2H , or $-OH$;

20

R_2 is selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-CHO$, $-CN$, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6 \text{ alkyl})_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

25

R_1 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, $-C_1-C_6$ alkyl, $-C_3-C_{10}$ cycloalkyl, $-CHO$, halogen, $(CH_2)_6C(O)NH_2$ or a moiety of the formula $-L'-M'$:

0067024.092900

- 152 -

5 L¹ indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-S-$, $-O-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $C(O)C(O)X$, $-(CH_2)_n-N-(CH_2)_n$

M¹ is selected from:

- 10 a) H, the group of C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, C₃-C₁₀ cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -NO₂, -NH₂, -CN, or -CF₃; or
- 15 b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole,
- 20 the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -NO₂, -NH₂, -CN, or -CF₃; or
- 25 c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to, pyran, pyridine, pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine, thiadiazine, oxazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -NO₂, -NH₂, -
- 30 CN, -CF₃ or -OH; or

006260-1204960
Sub
P1
conf

- 153 -

- 5 d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, chromene, indole, isoindole, indoline, isoindoline, naphthalene, purine, indolizine, indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or naphthyridine, the bicyclic ring moiety being
10 optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH;

- R₄ is selected from the group of C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, -
15 (CH₂)_n-C₃-C₆ cycloalkyl, -(CH₂)_n-S-(CH₂)_n-C₃-C₆ cycloalkyl, -(CH₂)_n-O-(CH₂)_n-C₃-C₆ cycloalkyl, or the groups of:

- a) a moiety of the formulae -(CH₂)_n-A, -(CH₂)_n-S-A, or -(CH₂)_n-O-A, wherein A is the moiety:



20

wherein

D is H, C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, or -CF₃;

- B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably
25 1 to 2, substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂; or

- b) a moiety of the formula -L²-M², wherein:

Sub
A1
Cmt

006260-1207960

- 154 -

5 L^2 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-S-$, $-O-$,
 $-SO_2-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-$
 $(CH_2)_n-$, $-C(O)C(O)X$;
where $X = O, N$

10 M^2 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-
 C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being
optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl,
preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-$
 CF_3 ; or

15 i) a five-membered heterocyclic ring containing one or two ring
heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole,
thiophene, imidazole, pyrazole, pyrrolidine, or tetrazole, the five-membered
heterocyclic ring being optionally substituted by from 1 to 3 substituents selected
20 from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6
alkoxy, $-NO_2$, $-NH_2$, $-CN$, or $-CF_3$; or

 ii) a six-membered heterocyclic ring containing one, two or three ring
heteroatoms selected from N, S or O including, but not limited to pyridine,
25 pyrimidine, piperidine, piperazine, or morpholine, the six-membered heterocyclic ring
being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10}
alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-CHO$, $-NO_2$, $-$
 NH_2 , $-CN$, $-CF_3$ or $-OH$; or

30 iii) a bicyclic ring moiety containing from 8 to 10 ring atoms and
optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including,


Sub
Pat
Cm
09677021.092000

- 155 -

5 but not limited to benzofuran, indole, indoline, naphthalene, purine, or quinoline, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH;

10 n is an integer from 0 to 3;

R₉ is selected from -COOH, -C(O)-COOH, -(CH₂)_n-C(O)-COOH, -(CH₂)_n-COOH, (CH₂)_n-CH=CH-COOH, -(CH₂)_n-tetrazole, -CH₂-phenyl-C(O)-benzothiazole, or



15

or a moiety selected from the formulae -L³-M³;


wherein L³ is a bridging or linking moiety selected from a chemical bond, -(CH₂)_n, -S-, -O-, -SO₂-, -C(O)-, -(CH₂)_n-C(O)-, -(CH₂)_n-C(O)-(CH₂)_n-, -(CH₂)_n-O-(CH₂)_n-, (CH₂)_n-S-(CH₂)_n-, -C(Z)-N(R₆)-, -C(Z)-N(R₆)-(CH₂)_n-, -C(O)-C(Z)-N(R₆)-, -C(O)-C(Z)-N(R₆)-(CH₂)_n-, -C(Z)-NH-SO₂-, -C(Z)-NH-SO₂-(CH₂)_n-, -(CH₂)_n-S-(CH₂)_n-, -(CH₂)_n-SO-(CH₂)_n-, -(CH₂)_n-SO₂-(CH₂)_n-, or -(CH₂)_n-CH=CH-(CH₂)_n-O-;

20

09677021-092900
 Sub
 Af
 Cmt

- 156 -

5 M^3 is selected from the group of $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, tetrazole,



where R_8 , R_9 or R_{10} can be attached anywhere in the cyclic or bicyclic system,
 n is an integer from 0 to 3;


15 R_8 , in each appearance, is independently selected from H , $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, tetrazole, $-\text{C}(\text{O})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$.

006260-T207960

Sub
 P1
 Cont

- 157 -

5






n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C(O)}-\text{COOH}$, $-\text{C}_1-\text{C}_6$ alkyl, $-\text{O}-\text{C}_1-\text{C}_6$ alkyl, $-\text{NH}(\text{C}_1-\text{C}_6 \text{ alkyl})$, or $-\text{N}(\text{C}_1-\text{C}_6 \text{ alkyl})_2$;

n is an integer from 0 to 3;


15 R_{10} is selected from the group of H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C(O)}-\text{COOH}$, $-\text{C}_1-\text{C}_6$ alkyl, $-\text{O}-\text{C}_1-\text{C}_6$ alkyl, $-\text{NH}(\text{C}_1-\text{C}_6 \text{ alkyl})$, $-\text{N}(\text{C}_1-\text{C}_6 \text{ alkyl})_2$,



006260-1207960

Sub
A1
m¹⁰

- 158 -




15 n is an integer from 0 to 3;

09677021.092900
 Al
 cmf


- 159 -

- 5 R_{11} is selected from H, C_1-C_6 lower alkyl, C_1-C_6 cycloalkyl, $-CF_3$, $-COOH$, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$,



with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_5 , R_8 , R_9 , R_{10} , and/or R_{11} shall contain at least one


- 10 acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,




n is an integer from 0 to 3;

- 15 or a pharmaceutically acceptable salt thereof.

5. A compound of Claim 1 having the formulae:



or




wherein:

0067024.092900

- 160 -

- 5 R_1 is selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, $-S-C_1-C_{10}$ alkyl, preferably $-S-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl, benzyl, $-O$ -benzyl, $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$;
 10 or R_1 and R_1 are independently a moiety of the formulae:



15

20

R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)CH_3$, phenyl, $-O$ -phenyl, benzyl, $-O$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$;

00677024.092900

AI
 cont

- 161 -

5 R_1 is selected from $-(CH_2)_n-COOH$, $-(CH_2)_n-N-(C_1-C_6 \text{ alkyl})_2$, $-(CH_2)_n-NH-(C_1-C_6 \text{ alkyl})$, $-CF_3$, $C_1-C_6 \text{ alkyl}$, $C_3-C_3 \text{ cycloalkyl}$, $C_1-C_6 \text{ alkoxy}$, $-NH-(C_1-C_6 \text{ alkyl})$, $-N-(C_1-C_6 \text{ alkyl})_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$ phenyl, phenyl, O -phenyl, benzyl, O -benzyl, adamantyl, or morpholinyl, $-(CH_2)_n$ -phenyl- O -phenyl, $-(CH_2)_n$ -phenyl- CH_2 -phenyl, $-(CH_2)_n$ - O -phenyl- CH_2 -phenyl, $-(CH_2)_n$ -phenyl- $(O-CH_2$ -phenyl) $_2$, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, $C_1-C_6 \text{ alkyl}$, $C_1-C_6 \text{ alkoxy}$, $-NH_2$, $-NO_2$, $-CF_3$, CO_2H , or $-OH$;

15 R_2 is selected from H , halogen, $-CF_3$, $-OH$, $C_1-C_{10} \text{ alkyl}$, preferably $C_1-C_6 \text{ alkyl}$, $C_1-C_{10} \text{ alkoxy}$, preferably $C_1-C_6 \text{ alkoxy}$, $-CHO$, $-CN$, $-NO_2$, $-NH_2$, $-NH-C_1-C_6 \text{ alkyl}$, $-N(C_1-C_6 \text{ alkyl})_2$, $-N-SO_2-C_1-C_6 \text{ alkyl}$, or $-SO_2-C_1-C_6 \text{ alkyl}$;

20 R_3 is selected from H , $-CF_3$, $C_1-C_6 \text{ lower alkyl}$, $C_1-C_6 \text{ lower alkoxy}$, $C_3-C_{10} \text{ cycloalkyl}$, $-C_1-C_6 \text{ alkyl}$, $-C_3-C_{10} \text{ cycloalkyl}$, $-CHO$, halogen, $-(CH_2)_2C(O)NH_2$ or a moiety of the formula $-L^1-M^1$;

25 L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n-$, $-S-$, $-O-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, or $-(CH_2)_n-S-(CH_2)_n-$, $C(O)C(O)X$, or $-(CH_2)_n-N-(CH_2)_n$;

where X is O or N

M^1 is selected from:

30 a) H , the group of $C_1-C_6 \text{ lower alkyl}$, $C_1-C_6 \text{ lower alkoxy}$, $C_3-C_{10} \text{ cycloalkyl}$, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted

00677024-092900
Sub
P1
Cmt

- 162 -

5 by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -NO₂, -NH₂, -CN, or -CF₃; or

b) a five-membered heterocyclic ring containing one or two ring heteroatoms selected from N, S or O including, but not limited to, furan, pyrrole, thiophene, imidazole, pyrazole, isothiazole, isoxazole, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazole, pyrazoline, imidazole, tetrazole, oxathiazole, the five-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -NO₂, -NH₂, -CN, or -CF₃; or

15

c) a six-membered heterocyclic ring containing one, two or three ring heteroatoms selected from N, S or O including, but not limited to, pyran, pyridine, pyrazine, pyrimidine, pyridazine, piperidine, piperazine, tetrazine, thiazine, thiadiazine, oxazine, or morpholine, the six-membered heterocyclic ring being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH; or

20

d) a bicyclic ring moiety containing from 8 to 10 ring atoms and optionally containing from 1 to 3 ring heteroatoms selected from N, S or O including, but not limited to benzofuran, chromene, indole, isoindole, indoline, isoindoline, naphthalene, purine, indolizine, indazole, quinoline, isoquinoline, quinolizine, quinazoline, cinnoline, phthalazine, or naphthyridine, the bicyclic ring moiety being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₁₀ alkyl, preferably C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -NO₂, -NH₂, -CN, -CF₃ or -OH;

25

30

00677021.092900

Sub
A1
conf

- 163 -

5

R_4 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(CH_2)_n-C_3-C_6$ cycloalkyl, $-(CH_2)_n-S-(CH_2)_n-C_3-C_6$ cycloalkyl, $-(CH_2)_n-O-(CH_2)_n-C_3-C_6$ cycloalkyl, or the groups of:

10

a) a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:



wherein


D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

15

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;

20

R_5 is selected from $-COOH$, $-C(O)-COOH$, $-(CH_2)_n-C(O)-COOH$, $-(CH_2)_n-COOH$, $(CH_2)_n-CH=CH-COOH$, $-(CH_2)_n$ -tetrazole, or



or a moiety selected from the formulae $-L^3-M^3$,

25






006260-12077960

Sub
AF

- 164 -

5 wherein L^3 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-SO_2-$, $-C(O)-$, $-(CH_2)_n-C(O)-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, $-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;

M^1 is selected from the group of $-COOH$, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole,



10

where R_8 , R_9 can be attached anywhere in the cyclic or bicyclic system,
 n is an integer from 0 to 3;


15

R_8 , in each appearance, is independently selected from H , $-COOH$, $-(CH_2)_n-$
 $COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole, $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,

Sub
 H/
 cont

09677021.092900

- 165 -




n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-\text{C}_1-\text{C}_6$ alkyl, $-\text{O}-\text{C}_1-\text{C}_6$ alkyl, $-\text{NH}(\text{C}_1-\text{C}_6 \text{ alkyl})$, or $-\text{N}(\text{C}_1-\text{C}_6 \text{ alkyl})_2$;

n is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_1 , R_2 , R_3 , shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-\text{C}(\text{O})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$;



n is an integer from 0 to 3;


or a pharmaceutically acceptable salt thereof.

6. A compound of Claim 1 having the formulae:

09677021.092900

Sub
 11
 Conf

- 166 -




wherein:

R_1 is selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, $-S-C_1-C_{10}$ alkyl, preferably $-S-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl, benzyl, $-O$ -benzyl, $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$;

or R_1 and R_1 are independently a moiety of the formulae:

or a moiety of the formulae:



0967021.092900

Sub
 Ag
 mg

- 167 -

5

*Sub
of
mg*

R_6 is selected from H, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)CH_3$, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or -OH;

10

R_7 is selected from $-(CH_2)_n-COOH$, $-(CH_2)_n-N(C_1-C_6 \text{ alkyl})_2$, $-(CH_2)_n-NH(C_1-C_6 \text{ alkyl})$, $-CF_3$, C_1-C_6 alkyl, C_3-C_3 cycloalkyl, C_1-C_6 alkoxy, $-NH(C_1-C_6 \text{ alkyl})$, $-N(C_1-C_6 \text{ alkyl})_2$, pyridinyl, thienyl, furyl, pyrrolyl, quinolyl, $(CH_2)_n$ phenyl, phenyl, -O-phenyl, benzyl, -O-benzyl, adamantyl, or morpholinyl, $-(CH_2)_n$ -phenyl-O-phenyl, $-(CH_2)_n$ -phenyl- CH_2 -phenyl, $-(CH_2)_n$ -O-phenyl- CH_2 -phenyl, $-(CH_2)_n$ -phenyl-(O- CH_2 -phenyl), the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NH_2$, $-NO_2$, $-CF_3$, CO_2H , or -OH;

20

R_8 is selected from H, halogen, $-CF_3$, -OH, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, -CHO, -CN, $-NO_2$, $-NH_2$, $-NH-C_1-C_6$ alkyl, $-N(C_1-C_6 \text{ alkyl})_2$, $-N-SO_2-C_1-C_6$ alkyl, or $-SO_2-C_1-C_6$ alkyl;

25

R_9 is selected from H, $-CF_3$, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, $-C_1-C_6$ alkyl, $-C_3-C_{10}$ cycloalkyl, -CHO, halogen, $(CH_2)_n C(O)NH_2$ or a moiety of the formula $-L^1-M^1$:

30

L^1 indicates a linking or bridging group of the formulae $-(CH_2)_n$, $-C(O)-$, $-(CH_2)_n C(O)-$, $-(CH_2)_n C(O)-(CH_2)_n$, $-(CH_2)_n-O-(CH_2)_n$, or $-(CH_2)_n-S-(CH_2)_n$, $C(O)C(O)X$, $-(CH_2)_n-N-(CH_2)_n$;

00677021.092900

- 168 -

5 M^1 is selected from:

a) H, the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, C_3-C_{10} cycloalkyl, phenyl or benzyl, the cycloalkyl, phenyl or benzyl rings being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_{10} alkyl, preferably C_1-C_6 alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{CN}$, or $-\text{CF}_3$; or

R_1 is selected from the group of C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, $-(\text{CH}_2)_n-C_3-C_6$ cycloalkyl, $-(\text{CH}_2)_n-S-(\text{CH}_2)_n-C_3-C_6$ cycloalkyl, $-(\text{CH}_2)_n-O-(\text{CH}_2)_n-C_3-C_6$ cycloalkyl, or the groups of:

15 a) a moiety of the formulae $-(\text{CH}_2)_n-A$, $-(\text{CH}_2)_n-S-A$, or $-(\text{CH}_2)_n-O-A$, wherein A is the moiety:



wherein

20 D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-\text{CF}_3$;


B and C are independently selected from phenyl, pyridinyl, furyl, thienyl, pyrimidinyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{C}_1-\text{C}_6$ alkyl, C_1-C_6 alkoxy, or $-\text{NO}_2$;

25 R_2 is selected from $-\text{COOH}$, $-\text{C}(\text{O})-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $(\text{CH}_2)_n-\text{CH}=\text{CH}-\text{COOH}$, $-(\text{CH}_2)_n$ -tetrazole, or a moiety selected from the formulae $-\text{L}^3-\text{M}^3$;

- 169 -

- 5 wherein L^3 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, $-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;

M^3 is selected from the group of $-COOH$, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole,




where R_8 , R_9 can be attached anywhere in the cyclic or bicyclic system,
 n is an integer from 0 to 3;

R_8 , in each appearance, is independently selected from H, $-COOH$, $-(CH_2)_n-COOH$, $-(CH_2)_n-C(O)-COOH$, tetrazole, $-C(O)-NH_2$, $-(CH_2)_n-C(O)-NH_2$,

Sub
 A/
 cont

09677021.092900

- 170 -




n is an integer from 0 to 3;

R_9 is selected from H, halogen, $-\text{CF}_3$, $-\text{OH}$, $-\text{COOH}$, $-(\text{CH}_2)_n-\text{COOH}$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{COOH}$, $-\text{C}_1-\text{C}_6$ alkyl, $-\text{O}-\text{C}_1-\text{C}_6$ alkyl, $-\text{NH}(\text{C}_1-\text{C}_6$ alkyl), or $-\text{N}(\text{C}_1-\text{C}_6$ alkyl);

n is an integer from 0 to 3;

with a proviso that the complete moiety at the indole or indoline 1-position created by any combination of R_7 , R_8 , R_9 , shall contain at least one acidic moiety selected from or containing a carboxylic acid, a tetrazole, or a moiety of the formulae: $-\text{C}(\text{O})-\text{NH}_2$, $-(\text{CH}_2)_n-\text{C}(\text{O})-\text{NH}_2$,



n is an integer from 0 to 3;


or a pharmaceutically acceptable salt thereof.

Sub
 H
 and

09677021.092900


- 171 -

5 7. A compound of Claim 1 having the formulae:



wherein:


R_1 and R_1' are independently selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, $-S-C_1-C_{10}$ alkyl, preferably $-S-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl, benzyl, $-O$ -benzyl, $-S$ -benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-NO_2$, $-NH_2$, $-CN$, $-CF_3$, or $-OH$; or R_1 and R_1' are independently a moiety of the formulae:



0967021.092900

*Sub
of
cmf*

- 172 -



Sub
10
 R₆ is selected from H, C₁-C₆ alkyl, C₁-C₆ alkoxy, phenyl, -O-phenyl, benzyl, -O-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, -NO₂, -NH₂, -CN, -CF₃, or -OH;

15 R₇ is selected from -OH, -CF₃, C₁-C₆ alkyl, C₁-C₆ alkoxy, -NH-(C₁-C₆ alkyl), -N-(C₁-C₆ alkyl)₂, pyridinyl, thienyl, furyl, pyrrolyl, phenyl, -O-phenyl, benzyl, -O-benzyl, the rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, -CN, C₁-C₆ alkyl, C₁-C₆ alkoxy, -NO₂, -NH₂, -CF₃, or -OH;

20 R₂ is selected from H, halogen, -CF₃, -OH, -C₁-C₁₀ alkyl, preferably -C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -CN, -NO₂, -NH₂, -NH-C₁-C₆ alkyl, -N(C₁-C₆ alkyl)₂, -N-SO₂-C₁-C₆ alkyl, or -SO₂-C₁-C₆ alkyl;

25 R₃ is selected from H, -C₁-C₁₀ alkyl, preferably -C₁-C₆ alkyl, -(CH₂)_n-OH, (CH₂)_n-C(O)NH₂, -CH₂-O-(C₁-C₆ alkyl), -CH₂-O-CH₂-phenyl, -CH₂-N-(C₁-C₆ alkyl), -CH₂-N-CH₂-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, -CF₃ or -C₁-C₆ alkyl;

X is O or N
 n = 0 or 1;

00677021-099900

- 173 -

R_4 is a moiety of the formulae $-(CH_2)_n-A$, $-(CH_2)_n-S-A$, or $-(CH_2)_n-O-A$, wherein A is the moiety:




wherein


D is H, C_1-C_6 lower alkyl, C_1-C_6 lower alkoxy, or $-CF_3$;

B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, or $-NO_2$;

R_5 is a moiety selected from the groups of:



or



09677021.099900


Sub
 ant AT

- 174 -

- 5 wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, $-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;
where n is an integer from 0 to 5;

- 10 R_9 is selected from $-CF_3$, $-C_1-C_6$ alkyl, C_1-C_6 alkoxy, $-NH(C_1-C_6 \text{ alkyl})$, or $N(C_1-C_6 \text{ alkyl})_2$,
 n in each instance is independently selected as an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.

8. A compound of Claim 1 having the formulae:



wherein:

R_1 is selected from H, halogen, $-CF_3$, $-OH$, $-C_1-C_{10}$ alkyl, preferably $-C_1-C_6$ alkyl, $-S-C_1-C_{10}$ alkyl, preferably $-S-C_1-C_6$ alkyl, C_1-C_{10} alkoxy, preferably C_1-C_6 alkoxy, $-CN$, $-NO_2$, $-NH_2$, $-HN(C_1-C_6)$, $-N(C_1-C_6)_2$, phenyl, $-O$ -phenyl, $-S$ -phenyl,

Sub
A1
Cmt

0067024.092900

- 175 -

- 5 benzyl, -O-benzyl, -S-benzyl, the phenyl and benzyl rings of these groups being optionally substituted by from 1 to 3 substituents selected from halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, -NO₂, -NH₂, -CN, -CF₃, or -OH;

- 10 R₂ is selected from H, halogen, -CF₃, -OH, -C₁-C₁₀ alkyl, preferably -C₁-C₆ alkyl, C₁-C₁₀ alkoxy, preferably C₁-C₆ alkoxy, -CHO, -CN, -NO₂, -NH₂, -NH-C₁-C₆ alkyl, -N(C₁-C₆ alkyl)₂, -N-SO₂-C₁-C₆ alkyl, or -SO₂-C₁-C₆ alkyl;

- 15 R₃ is selected from H, -C₁-C₁₀ alkyl, preferably -C₁-C₆ alkyl, -(CH₂)-OH, (CH₂)_nC(O)NH₂, -CH₂-O-(C₁-C₆ alkyl), -CH₂-O-CH₂-phenyl, -CH₂-N-(C₁-C₆ alkyl), -CH₂-N-CH₂-phenyl, the phenyl rings of which are optionally substituted by 1 or 2 groups selected from H, halogen, -CF₃ or -C₁-C₆ alkyl;

n = 0 or 1.

- 20 R₄ is a moiety of the formulae -(CH₂)_n-A, -(CH₂)_n-S-A, or -(CH₂)_n-O-A, wherein A is the moiety:



wherein

- 25 D is H, C₁-C₆ lower alkyl, C₁-C₆ lower alkoxy, or -CF₃;
B and C are independently selected from phenyl, pyridinyl, furyl, thienyl or pyrrolyl groups, each optionally substituted by from 1 to 3, preferably 1 to 2, substituents selected from H, halogen, -CF₃, -OH, -C₁-C₆ alkyl, C₁-C₆ alkoxy, or -NO₂;


006260.1207960

Sub
H1
CMT

- 176 -

5

R₅ is a moiety selected from the groups of:



10

wherein L¹ is a bridging or linking moiety selected from a chemical bond, -(CH₂)_n-, -(CH₂)_n-C(O)-(CH₂)_n-, -(CH₂)_n-O-(CH₂)_n-, -(CH₂)_n-S-(CH₂)_n-, -(CH₂)_n-SO-(CH₂)_n-, -(CH₂)_n-SO₂-(CH₂)_n-, or -(CH₂)_n-CH=CH-(CH₂)_n-O-;

where n = 0-5

15


R₉ is selected from -CF₃, -C₁-C₆ alkyl, C₁-C₆ alkoxy, -NH(C₁-C₆ alkyl), or -N(C₁-C₆ alkyl)₂,

n in each instance is independently selected as an integer from 0 to 3
 20 or a pharmaceutically acceptable salt thereof

0067024.092900

- 177 -

5 9. A compound of Claim 1 having the formulae:



wherein:

R₁ is selected from H, halogen, -CF₃, -OH, -CN, -NO₂, -NH₂, -HN(C₁-C₆), -
 10 N(C₁-C₆)₂, phenyl, -N-SO₂-C₁-C₆ alkyl, or -SO₂-C₁-C₆ alkyl;

R₂ is selected from H, halogen, -CF₃, -OH, , -CN, -NO₂, -NH₂, -NH-C₁-C₆
 alkyl, -N(C₁-C₆ alkyl)₂, -N-SO₂-C₁-C₆ alkyl, or -SO₂-C₁-C₆ alkyl;


15 R₃ is selected from H, -C₁-C₁₀ alkyl, preferably -C₁-C₆ alkyl, -(CH₂)_n-OH,
 (CH₂)_n-C(O)NH₂, -CH₂-O-(C₁-C₆ alkyl), -CH₂-O-CH₂-phenyl, -CH₂-N-(C₁-C₆ alkyl), -
 CH₂-N-CH₂-phenyl, the phenyl rings of which are optionally substituted by 1 or 2
 groups selected from H, halogen, -CF₃ or -C₁-C₆ alkyl;

20 n = 0 or 1.

R₅ is a moiety selected from the groups of:

006260-1207960
 Sub
 P1
 Cont

- 178 -



wherein L^1 is a bridging or linking moiety selected from a chemical bond, $-(CH_2)_n-$, $-(CH_2)_n-C(O)-(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_n-$, $-(CH_2)_n-S-(CH_2)_n-$, $-(CH_2)_n-SO-(CH_2)_n-$, $-(CH_2)_n-SO_2-(CH_2)_n-$, or $-(CH_2)_n-CH=CH-(CH_2)_n-O-$;

10 n in each instance is independently selected as an integer from 0 to 5; or a pharmaceutically acceptable salt thereof.

15 10. A compound of Claim 1 which is 4-[(E)-4-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)-2-butenyl]oxy]benzoic acid or a pharmaceutically acceptable salt thereof.

11. A compound of Claim 1 which is 4-[2-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)ethoxy]benzoic acid or a pharmaceutically acceptable salt thereof.

20

006260"1207960

Sub
Alt
Cont

- 179 -

5 12. A compound of Claim 1 which is 3-{4-[2-(3-benzhydryl-5-chloro-2-methyl-1H-indol-1-yl)ethoxy]phenyl}propanoic acid or a pharmaceutically acceptable salt thereof.

10 13. A compound of Claim 1 which is 3-{4-[[2-(3-benzhydryl-6-chloro-1H-indol-1-yl)ethyl]sulfonyl]phenyl}propanoic acid or a pharmaceutically acceptable salt thereof.

15 14. A compound of Claim 1 which is 4-{[2-(3-benzhydryl-6-chloro-1H-indol-1-yl)ethyl]sulfonyl}benzoic acid or a pharmaceutically acceptable salt thereof.

 15. A compound of Claim 1 which is 4-[2-(3-benzhydryl-2-methyl-1H-indol-1-yl)ethoxy]benzoic acid or a pharmaceutically acceptable salt thereof.

20 16. A method of inhibiting the phospholipase activity of an enzyme in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

25 17. A method of treating or preventing an inflammatory response in a mammal in need thereof, the method comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

30 18. The method of Claim 17 wherein the inflammatory response is associated with inflammatory bowel disease.

09677021-092900

- 180 -

5 19. The method of Claim 17 wherein the inflammatory response is
associated with osteoarthritis, psoriatic arthritis or rheumatoid arthritis.

 20. A pharmaceutical composition comprising a therapeutically effective
amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, and
10 a pharmaceutically acceptable carrier.

006260-72077960